Kenvue Inc. (KVUE)
| Market Cap | 34.33B -2.4% |
| Revenue (ttm) | 15.41B +1.8% |
| Net Income | 1.66B +16.9% |
| EPS | 0.85 +14.9% |
| Shares Out | 1.92B |
| PE Ratio | 21.06 |
| Forward PE | 14.79 |
| Dividend | $0.84 (4.69%) |
| Ex-Dividend Date | Sep 21, 2026 |
| Volume | 5,704,001 |
| Open | 17.95 |
| Previous Close | 17.67 |
| Day's Range | 17.89 - 17.99 |
| 52-Week Range | 14.02 - 20.13 |
| Beta | 0.43 |
| Analysts | Hold |
| Price Target | 19.50 (+9.09%) |
| Earnings Date | Nov 2, 2026 |
About KVUE
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral a... [Read more]
Financial Performance
In 2025, Kenvue's revenue was $15.12 billion, a decrease of -2.14% compared to the previous year's $15.46 billion. Earnings were $1.47 billion, an increase of 42.72%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for KVUE stock is "Hold." The 12-month stock price target is $19.5, which is an increase of 9.09% from the latest price.
News
Kimberly-Clark readies EU remedies in bid for Kenvue deal, sources say
Kimberly-Clark is readying concessions to address EU antitrust concerns about its bid for Tylenol maker Kenvue that could help it win approval for the $40 billion deal after a preliminary review,...
My Favorite Consumer Staples Play Right Now
Owning consumer staples stocks is an absolute must in a dividend investing strategy. Most people turn to dividend stocks for two reasons — to generate income or to put the magic of compounding to work...
Kenvue Declares Quarterly Cash Dividend
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.21 per share on its common stock. The quarterly dividend is paya...
Tylenol use in pregnancy may be linked with uterus, ovary changes in daughters
Female reproductive organ development may be impacted by a mother's use of Tylenol during pregnancy, according to researchers who emphasize that their study does not prove the pain medicine is to bl...
Australia clears Kimberly-Clark's acquisition of Kenvue but requires Carefree, Stayfree divestment
Australia's competition regulator on Wednesday approved Kimberly-Clark's proposed $40 billion takeover of Kenvue , on condition the company divests Kenvue's Carefree and Stayfree period care brands ...
Kimberly-Clark seeks EU approval for $40 billion Kenvue deal
Kimberly-Clark has asked EU regulators permission for its proposed $40 billion takeover of Tylenol maker Kenvue, documents on the EU Commission's website showed.
Kimberly-Clark Appoints Suzana Blades as Senior Vice President and General Counsel
Accomplished legal executive and global litigator brings proven track record of enterprise risk management and strategic leadership to support Kimberly-Clark's next chapter of growth DALLAS, Aug. 13, ...
Kenvue Quarterly report: Q2 2026
Kenvue has published its Q2 2026 quarterly earnings report on August 6, 2026.
Kenvue Earnings release: Q2 2026
Kenvue released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Kenvue misses quarterly estimates as inflation, tariffs squeeze margins
Kenvue narrowly missed Wall Street estimates for second-quarter results on Thursday as inflation, tariffs and currency-related costs squeezed margins.
Kenvue Posts Higher Profit, Sales as Turnaround Continues
Kenvue reported higher profit and sales in the second quarter, boosted by higher prices and volumes, as the company continues working to turn around its business ahead of its acquisition by Kimberly-C...
Kenvue Reports Second Quarter 2026 Results
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced financial results for the fiscal second quarter ended June 28, 2026. “We delivered our third consecutive quarter of net and orga...
Drugmakers, retailers must face 'maximum strength' claim in decongestant false ad litigation in US
A federal appeals court on Thursday revived portions of nationwide litigation in which consumers accused drugmakers such as Procter & Gamble and retailers such as CVS of selling billions of dollars o...
Kenvue Increases Quarterly Cash Dividend
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.21 per share on its common stock, which represents a 1.2 percent...
US FDA approves over-the-counter Tylenol combination pill for pain relief
The U.S. Food and Drug Administration on Friday approved a nonprescription, fixed-dose pill that combines Kenvue's Tylenol with the nonsteroidal anti-inflammatory drug naproxen for up to 12 hours of...
Kenvue to Announce Second Quarter 2026 Results on August 6, 2026
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce its second quarter 2026 financial results before the market opens on August 6, 2026. Due to the pending transaction with Kimberly-...
US appeals court revives private lawsuits linking Tylenol to autism, ADHD
A federal appeals court on Monday revived hundreds of private lawsuits against Kenvue and many pharmacies and retailers, alleging that the Tylenol painkiller causes autism and attention deficit...
Kenvue Transcript: AGM 2026
The meeting confirmed a quorum and proceeded with the election of 12 directors, approval of executive compensation, and ratification of the auditor. All proposals passed, with final results to be filed in a Form 8-K.
Kenvue Earnings release: Q1 2026
Kenvue released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Kenvue Quarterly report: Q1 2026
Kenvue has published its Q1 2026 quarterly earnings report on May 7, 2026.
Kenvue beats first-quarter estimates amid pending acquisition by Kimberly-Clark
Tylenol-maker Kenvue on Thursday beat Wall Street estimates for first-quarter revenue and profit helped by strong sales in its skin health and beauty brands.
Kenvue Reports First Quarter 2026 Results
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced financial results for the fiscal first quarter ended March 29, 2026. “Our year is off to an encouraging start, as our continued ...
Kenvue to Announce First Quarter 2026 Results on May 7, 2026
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce its first quarter 2026 financial results before the market opens on May 7, 2026. Due to the pending transaction with Kimberly-Clar...